Suggested remit: To appraise the clinical and cost effectiveness of blinatumomab with chemotherapy within its marketing authorisation for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Appraisal in progress
Process STA Standard
ID number 6405

Provisional Schedule

Committee meeting 16 January 2025
Expected publication 26 March 2025

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Amgen Ltd (blinatumomab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Leukaemia Care
  Blood Cancer UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Accord UK Ltd (cytarabine, doxorubicin, etoposide, methotrexate) (confidentiality agreement not signed, not participating)
  ADVANZ Pharma (methotrexate) (confidentiality agreement not signed, not participating)
  Almus Pharmaceuticals Ltd (methotrexate) (confidentiality agreement not signed, not participating)
  Aspen Pharma Trading Ltd (mercaptopurine) (confidentiality agreement not signed, not participating)
  Baxter Healthcare Ltd (doxorubicin, cyclophosphamide) (confidentiality agreement not signed, not participating)
  Cipla EU Ltd (methotrexate) (confidentiality agreement not signed, not participating)
  Consilient Health Ltd (etoposide) (confidentiality agreement not signed, not participating)
  Esteve Pharmaceuticals Ltd (methotrexate) (confidentiality agreement not signed, not participating)
  Fontus Health Ltd (mercaptopurine) (confidentiality agreement not signed, not participating)
  Fresenius Kabi Ltd (etoposide) (confidentiality agreement not signed, not participating)
  Hospira UK Ltd (cytarabine, methotrexate, vincristine) (confidentiality agreement not signed, not participating)
  Jazz Pharmaceuticals UK (cytarabine, daunorubicin) (confidentiality agreement not signed, not participating)
  medac GmbH (asparaginase, doxorubicin, etoposide, methotrexate) (confidentiality agreement not signed, not participating)
  Medihealth (Northern) Ltd (mercaptopurine, methotrexate) (confidentiality agreement not signed, not participating)
  Morningside Healthcare Ltd (methotrexate) (confidentiality agreement not signed, not participating)
  Neon Healthcare Ltd (etoposide) (confidentiality agreement not signed, not participating)
  Nordic Pharma Ltd (methotrexate) (confidentiality agreement not signed, not participating)
  Nova Laboratories Ltd (mercaptopurine) (confidentiality agreement not signed, not participating)
  Orion Pharma (UK) Ltd (methotrexate) (confidentiality agreement not signed, not participating)
  Pfizer Ltd (cytarabine, doxorubicin, methotrexate, vincristine) (confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals Ltd (methotrexate) (confidentiality agreement not signed, not participating)
  Sandoz Ltd (cyclophosphamide, methotrexate) (confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals Ltd (doxorubicin) (confidentiality agreement not signed, not participating)
  Sigma Pharmaceuticals Plc (methotrexate) (confidentiality agreement not signed, not participating)
  Teva Ltd (methotrexate, vincristine) (confidentiality agreement not signed, not participating)
  Therakind Ltd (methotrexate) (confidentiality agreement not signed, not participating)
  Zentiva Pharma UK Ltd (daunorubicin) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
28 June 2024 Invitation to participate
24 April 2024 - 23 May 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 April 2024 In progress
21 February 2024 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual